Checkpoint Inhibitors in Lung Cancer Are Not Immune from Cost-Effectiveness Analysis.

[1]  S. Aebi,et al.  A Cost‐Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD‐L1 Testing , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  A. Abernethy,et al.  Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  R. Motzer,et al.  Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. , 2016, The Lancet. Oncology.

[4]  D. Rousseau,et al.  A Snapshot of Cancer Spending and Outcomes. , 2016, JAMA.

[5]  R. Goeree,et al.  Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes , 2016, Journal of medical economics.

[6]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[7]  M. Piccart,et al.  A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Adam P Dicker,et al.  American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Thomas J. Smith,et al.  Cost effectiveness of crizotinib for anaplastic lymphoma kinase-positive, non-small-cell lung cancer: who is going to blink at the cost? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Gridelli,et al.  Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  J. Pignon,et al.  Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 , 2011, European Respiratory Journal.

[12]  Thomas J. Smith,et al.  Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.